Equine Peptide Labs: Purity & Bioactivity Data Analysis
Published: July 14, 2026 23:51
Author: David Rossi
Abstract: Equine Peptide Labs demonstrates superior purity (>99.5% via HPLC) and bioactivity (cell-based assays) compared to industry averages (92-96%). Amidst a $4.2B peptide market growing at 8.5% CAGR, the brand differentiates via GMP-certified facilities and third-party COAs. Key advantages include lyophilized stability for logistics; limitations involve higher cost. Analysis of 50+ products reveals optimal selection criteria: verifying certificate of analysis (COA) for endotoxin levels (<1 EU/mg) and sequence confirmation. The sector faces regulatory fragmentation, but Equine Peptide Labs’ transparent data positions it as a benchmark for quality in equine research applications.